Biomarkers /
ABL1
Back to Biomarkers List
Overview
ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) is a gene that encodes a protein non-receptor tyrosine kinase with DNA-binding activity. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as hematopoietic and lymphoid cancers.
Biomarker-Directed Therapies
ABL1 is a predictive biomarker for use of dasatinib, ponatinib, bosutinib, nilotinib, and imatinib in patients.
Chronic myeloid leukemia and acute lymphoblastic leukemia have the most therapies with ABL1 as a predictive biomarker.
Of the therapies with ABL1 as a predictive biomarker, 4 are FDA-approved in at least one clinical setting and 5 have NCCN guidelines in at least one clinical setting.
BCR-ABL1 Fusion, ABL1 T315I, ABL1 F317L, ABL1 E255K, and ABL1 E255V are the top alterations on ABL1 targeted by therapies [4].
Bosutinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Dasatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN), Treatment Induction (NCCN) | |
| Note: Not recommended as a single agent for patients 40 years and older with Ph-positive ALL. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (NCCN), Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (MCG), Relapse (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Imatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Relapse (FDA) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Nilotinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN) | |
| Note: Resistance or intolerant to prior therapy that included imatinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Applies if the cancer is resistant or intolerant to prior therapy that included imatinib. |
Ponatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN) | |
| Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase). |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN) | |
| Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase). |
Clinical Trials
ABL1 status serves as an inclusion eligibility criteria in 249 clinical trials, of which 162 are open and 87 are closed. Of the trials that contain ABL1 status as an inclusion criterion, 2 are early phase 1 (1 open), 55 are phase 1 (26 open), 36 are phase 1/phase 2 (23 open), 114 are phase 2 (84 open), 4 are phase 2/phase 3 (3 open), 26 are phase 3 (18 open), 7 are phase 4 (5 open), and 5 are no phase specified (2 open).
Trials with ABL1 status in the inclusion eligibility criteria most commonly target acute lymphoblastic leukemia, chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, multiple myeloma, and urothelial carcinoma [4].
The most frequent alteration to serve as an inclusion eligibility criterion is BCR-ABL1 Fusion [4].
Cyclophosphamide, blinatumomab, dexamethasone, doxorubicin, and ponatinib are the most frequent therapies in trials with ABL1 as an inclusion criteria [4].
Significance of ABL1 in Diseases
Chronic Myeloid Leukemia +
ABL1 is an inclusion criterion in 116 clinical trials for chronic myeloid leukemia, of which 75 are open and 41 are closed. Of the trials that contain ABL1 status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 24 are phase 1 (11 open), 20 are phase 1/phase 2 (13 open), 52 are phase 2 (40 open), 11 are phase 3 (7 open), 5 are phase 4 (3 open), and 3 are no phase specified (1 open) [4].
Dasatinib, nilotinib, ponatinib, bosutinib, and imatinib have evidence of efficacy in patients with ABL1 mutation in chronic myeloid leukemia [4].
Acute Lymphoblastic Leukemia +
ABL1 is an inclusion criterion in 94 clinical trials for acute lymphoblastic leukemia, of which 61 are open and 33 are closed. Of the trials that contain ABL1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 23 are phase 1 (11 open), 11 are phase 1/phase 2 (9 open), 44 are phase 2 (29 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), 2 are phase 4 (2 open), and 3 are no phase specified (1 open) [4].
Ponatinib, bosutinib, dasatinib, imatinib, and nilotinib have evidence of efficacy in patients with ABL1 mutation in acute lymphoblastic leukemia [4].
Acute Myeloid Leukemia +
ABL1 is an inclusion criterion in 118 clinical trials for acute myeloid leukemia, of which 68 are open and 50 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 32 are phase 1 (15 open), 22 are phase 1/phase 2 (16 open), 48 are phase 2 (29 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 2 are no phase specified (0 open) [4].
Myelodysplastic Syndromes +
ABL1 is an inclusion criterion in 75 clinical trials for myelodysplastic syndromes, of which 44 are open and 31 are closed. Of the trials that contain ABL1 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 24 are phase 1 (11 open), 12 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (0 open) [4].
Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain ABL1 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].
B-Cell Acute Lymphoblastic Leukemia +
ABL1 is an inclusion criterion in 21 clinical trials for B-cell acute lymphoblastic leukemia, of which 17 are open and 4 are closed. Of the trials that contain ABL1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 7 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].
Multiple Myeloma +
ABL1 is an inclusion criterion in 21 clinical trials for multiple myeloma, of which 14 are open and 7 are closed. Of the trials that contain ABL1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].
Non-Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 19 clinical trials for non-hodgkin lymphoma, of which 11 are open and 8 are closed. Of the trials that contain ABL1 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (6 open) [4].
Acute Biphenotypic Leukemia +
ABL1 is an inclusion criterion in 17 clinical trials for acute biphenotypic leukemia, of which 8 are open and 9 are closed. Of the trials that contain ABL1 status and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (3 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Chronic Myelomonocytic Leukemia +
ABL1 is an inclusion criterion in 16 clinical trials for chronic myelomonocytic leukemia, of which 11 are open and 5 are closed. Of the trials that contain ABL1 status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].
Chronic Lymphocytic Leukemia +
ABL1 is an inclusion criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 6 are closed. Of the trials that contain ABL1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [4].
Acute Leukemia +
ABL1 is an inclusion criterion in 11 clinical trials for acute leukemia, of which 4 are open and 7 are closed. Of the trials that contain ABL1 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Mantle Cell Lymphoma +
ABL1 is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 5 are open and 6 are closed. Of the trials that contain ABL1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Burkitt Lymphoma +
ABL1 is an inclusion criterion in 10 clinical trials for Burkitt lymphoma, of which 4 are open and 6 are closed. Of the trials that contain ABL1 status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Anaplastic Large Cell Lymphoma +
ABL1 is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 5 are closed. Of the trials that contain ABL1 status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Myeloproliferative Neoplasm +
ABL1 is an inclusion criterion in 9 clinical trials for myeloproliferative neoplasm, of which 5 are open and 4 are closed. Of the trials that contain ABL1 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].
Follicular Lymphoma +
ABL1 is an inclusion criterion in 8 clinical trials for follicular lymphoma, of which 3 are open and 5 are closed. Of the trials that contain ABL1 status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Juvenile Myelomonocytic Leukemia +
ABL1 is an inclusion criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain ABL1 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Lymphoma +
ABL1 is an inclusion criterion in 8 clinical trials for lymphoma, of which 4 are open and 4 are closed. Of the trials that contain ABL1 status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [4].
Marginal Zone Lymphoma +
ABL1 is an inclusion criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain ABL1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Lymphoblastic Lymphoma +
ABL1 is an inclusion criterion in 7 clinical trials for lymphoblastic lymphoma, of which 5 are open and 2 are closed. Of the trials that contain ABL1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].
Myelofibrosis +
ABL1 is an inclusion criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain ABL1 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [4].
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +
ABL1 is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain ABL1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Diffuse Large B-Cell Lymphoma +
ABL1 is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain ABL1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [4].
Mixed Phenotype Acute Leukemia +
ABL1 is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain ABL1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].
Prolymphocytic Leukemia +
ABL1 is an inclusion criterion in 6 clinical trials for prolymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain ABL1 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Refractory Anemia With Excess Blasts +
ABL1 is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 2 are open and 4 are closed. Of the trials that contain ABL1 status and refractory anemia with excess blasts as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].
Secondary Acute Myeloid Leukemia +
ABL1 is an inclusion criterion in 6 clinical trials for secondary acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain ABL1 status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
T-Cell Acute Lymphoblastic Leukemia +
ABL1 is an inclusion criterion in 6 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 1 is closed. Of the trials that contain ABL1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Lymphoplasmacytic Lymphoma +
ABL1 is an inclusion criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain ABL1 status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm +
ABL1 is an inclusion criterion in 5 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 4 are open and 1 is closed. Of the trials that contain ABL1 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].
Small Lymphocytic Lymphoma +
ABL1 is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain ABL1 status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +
ABL1 is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Acute Undifferentiated Leukemia +
ABL1 is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 3 are open and 1 is closed. Of the trials that contain ABL1 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].
B-Cell Non-Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ABL1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Double-Hit Lymphoma +
ABL1 is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ABL1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].
Malignant Solid Tumor +
ABL1 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Refractory Anemia +
ABL1 is an inclusion criterion in 4 clinical trials for refractory anemia, of which 1 is open and 3 are closed. Of the trials that contain ABL1 status and refractory anemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Therapy-Related Myelodysplastic Syndrome +
ABL1 is an inclusion criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Myelodysplastic Syndrome With Excess Blasts-2 +
ABL1 is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain ABL1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [4].
Plasma Cell Leukemia +
ABL1 is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain ABL1 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].
T-Cell Lymphoblastic Leukemia/Lymphoma +
ABL1 is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ABL1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].
Therapy-Related Acute Myeloid Leukemia +
ABL1 is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ABL1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Acute Erythroid Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Acute Megakaryoblastic Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Acute Promyelocytic Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [4].
Adult T-Cell Leukemia/Lymphoma +
ABL1 is an inclusion criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain ABL1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [4].
B-Cell Prolymphocytic Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].
Burkitt Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].
Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Mature T-Cell And NK-Cell Lymphoma/Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain ABL1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].
Mature T-Cell And NK-Cell Neoplasm +
ABL1 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].
Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +
ABL1 is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Peripheral T-Cell Lymphoma +
ABL1 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].
T-Cell Non-Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].
T-Cell Prolymphocytic Leukemia +
ABL1 is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Urothelial Carcinoma +
ABL1 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Acute Bilineal Leukemia +
ABL1 is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Acute Leukemia Of Ambiguous Lineage +
ABL1 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].
Acute Myeloid Leukemia With Myelodysplasia-Related Changes +
ABL1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
ABL1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].
Adult Acute Lymphoblastic Leukemia +
ABL1 is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Aplastic Anemia +
ABL1 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoblastic Leukemia/Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and B-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoblastic Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Bladder Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cancer +
ABL1 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].
Desmoplastic Small Round Cell Tumor +
ABL1 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Esophageal Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ewing Sarcoma +
ABL1 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Gastric Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gastrointestinal Stromal Tumor +
ABL1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Hepatobiliary Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Indolent Non-Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lip And Oral Cavity Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Salivary Gland Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Mature B-Cell Lymphoma/Leukemia +
ABL1 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Mediastinal Large B-Cell Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Melanoma +
ABL1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and melanoma as inclusion criteria, 1 is no phase specified (0 open) [4].
Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +
ABL1 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +
ABL1 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Myelodysplastic Syndrome With Excess Blasts-1 +
ABL1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
ABL1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Myeloid Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Myeloid Sarcoma +
ABL1 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasopharyngeal Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuroblastoma +
ABL1 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Non-Small Cell Lung Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Oropharyngeal Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Pancreatic Carcinoma +
ABL1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Plasma Cell Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Polycythemia Vera +
ABL1 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Myelofibrosis +
ABL1 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Rhabdomyosarcoma +
ABL1 is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Secondary Myelodysplastic Syndrome +
ABL1 is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Lymphocytic Leukemia +
ABL1 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Solid Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and solid neoplasm as inclusion criteria, 1 is no phase specified (0 open) [4].
T-Cell Lymphoblastic Lymphoma +
ABL1 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
T-Cell And NK-Cell Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Therapy-Related Chronic Myelomonocytic Leukemia +
ABL1 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Therapy-Related Myeloid Neoplasm +
ABL1 is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Waldenstrom Macroglobulinemia +
ABL1 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
